ASCO has developed a free educational series to help the oncology community learn more about the role of social determinants of health in cancer care and cancer outcomes.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
JCO Oncology Practice recently published an editorial that examines the intensified burnout oncology practitioners are experiencing due the COVID-19 pandemic and outlines critical interventions to support oncologists now and throughout a long-term recovery. The article was written by past, current, and select members of the American Society of Clinical Oncology’s (ASCO) Ethics Committee and Clinician Well-Being Task Force.
On February 9, 2021, the Food and Drug Administration granted regular approval to cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for patients with locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate and granted accelerated approval to cemiplimab-rwlc for patients with metastatic BCC (mBCC) previously treated with a HHI or for whom a HHI is not appropriate.
The American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients. The joint recommendations are detailed in a series of articles published in Clinical Cancer Research, a journal of the American Association for Cancer Research. The series provides a comprehensive examination of eligibility criteria for cancer clinical trials with recommendations to address five specific areas: treatment washout periods, concomitant medications, prior therapies, laboratory reference ranges and test intervals, and patient performance status.
On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib (Ukoniq, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for the specific indications.
On February 5, 2021, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
On February 3, 2021, the Food and Drug Administration granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
President Biden signed an executive order (EO) that will reopen HealthCare.gov—the federal health insurance exchange—for a special, three-month enrollment period starting on February 15, 2021. The Association for Clinical Oncology (the Association) applauds this decision, which was a recommendation in American Society of Clinical Oncology’s (the Society) Road to Recovery Report: Learning from the COVID-19 Experience to Improve Clinical Research and Cancer Care. Reopening the federal health insurance exchange will help provide coverage to the millions of Americans who have lost their health insurance amid the COVID-19 pandemic.
A new article published in JCO Oncology Practice puts forth a framework to guide researchers, healthcare leaders, advocates, community- and patient-focused service organizations, and policy leaders in their work to address and promote health equity in cancer care access and treatment outcomes.
The American Society of Clinical Oncology issued a new position statement strongly opposing the use of copay accumulator programs and copay maximizer programs for individuals with cancer. The statement also makes recommendations to protect patients from the potential harms of such programs.
In the days and weeks leading up to President Biden’s inauguration, the Department of Health and Human Services (HHS)—under the prior administration—issued a number of rules and regulations that affect cancer care delivery. Many of those rules and regulations are now subject to review by the new administration and/or Congress.
Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and white Americans have been selected to participate in the American Society of Clinical Oncology’s (ASCO) quality programs, including the Quality Oncology Practice Initiative (QOPI®) and Quality Training Program (QTP). Today ASCO and Susan G. Komen (Komen), with funding from the Fund II Foundation for each practice’s training and participation, announced the recipients. The three-year program, will be administered through Conquer Cancer, the ASCO Foundation.
On January 22, 2021, the Food and Drug Administration approved the combination of nivolumab (Opdivo, Bristol-Myers Squibb Co.) and cabozantinib (Cabometyx, Exelixis) as first-line treatment for patients with advanced renal cell carcinoma (RCC).
On January 15, 2021, the Food and Drug Administration granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, Janssen Biotech Inc.) in combination with bortezomib, cyclophosphamide and dexamethasone for newly diagnosed light chain (AL) amyloidosis.
On January 15, 2021, the U.S. Food and Drug Administration is alerting health care professionals to labeling updates for the preparation of vinca alkaloids, a group of chemotherapy agents that includes vincristine sulfate injection, vinblastine sulfate (for) injection, and vinorelbine tartrate injection. To reduce the potential for unintended intrathecal (spinal) administration, which causes death or severe neurological injury, FDA is working with drug application holders to remove instructions for preparation of these drugs by syringe and to recommend preparation in intravenous infusion bags only.